OctoPlus wins new drug delivery evaluation contract
As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. announced that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Mouse stem cell study offers new insights into body fat distribution
Pharmexa adds two strong new members to board of directors
Alnylam Grants Dharmacon License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
Enzyme inhibitor takes an unexpected approach toward blocking cancer-promoting protein
